<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4898">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576534</url>
  </required_header>
  <id_info>
    <org_study_id>P00028603</org_study_id>
    <nct_id>NCT03576534</nct_id>
  </id_info>
  <brief_title>Pre Bypass Ultrafiltration (PBUF) in Children Requiring Cardiopulmonary Bypass</brief_title>
  <acronym>PBUF</acronym>
  <official_title>Pre Bypass Ultrafiltration (PBUF) Improves Intraoperative Glucose, Sodium, Potassium and Lactate Levels in Children Requiring Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Newborn babies and children with congenital heart defects who need heart surgery need to be&#xD;
      placed on the heart-lung machine for heart surgery.&#xD;
&#xD;
      In order to use the heart-lung machine, the investigators have to use blood and other fluids&#xD;
      to fill the tubing. During the operation, ultrafiltration is carried out as standard of care&#xD;
      to remove extra fluid. Modified ultrafiltration is also performed after surgery. In this&#xD;
      study, the investigators are looking to use the filter additionally before surgery. Using the&#xD;
      pre bypass filtration before the subject is placed on the heart-lung machine will allow the&#xD;
      investigators to better normalize electrolytes in the blood/fluid mixture used in the heart&#xD;
      lung machine. This technique is called pre-bypass ultrafiltration, or PBUF (pronounced &quot;P&quot;&#xD;
      Buff).&#xD;
&#xD;
      The investigators are conducting a study to see if using PBUF to better normalize&#xD;
      electrolytes in the blood will make a difference. The investigators have been adding fluids&#xD;
      to prime the heart-lung machine in two different ways. The investigators believe both methods&#xD;
      are safe and acceptable but hypothesize that there may be subtle differences in electrolytes&#xD;
      and fluid status when one technique is used as opposed to the other. The investigators&#xD;
      believe that neither technique introduces risk since both are currently used in practice. The&#xD;
      standard method adds blood to the heart-lung machine. The alternate method adds blood to the&#xD;
      heart-lung machine and then additional fluid is added and removed to more normalize the&#xD;
      electrolytes. The investigators plan to randomized subjects undergoing heart surgery to&#xD;
      receive the standard priming method versus PBUF to determine if there is any difference in&#xD;
      outcomes. Laboratory and clinical data collected as part of clinical care will be used to&#xD;
      determine difference sin outcomes. There will be no additional blood taken for this study.&#xD;
&#xD;
      There are no known risks to PBUF. The benefits include helping investigators determine if&#xD;
      PBUF does or does not make a difference to how subjects recover after surgery. The&#xD;
      investigators believe that providing more normal blood values will either improve the&#xD;
      subjects' outcome or have no benefit. The investigators do not anticipate increased risks.&#xD;
&#xD;
      Given COVID -19 restrictions, the study is on hold.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research question: Can PBUF provide more physiologic values for glucose, sodium, potassium&#xD;
      and lactate throughout the cardiopulmonary bypass period without an increased incidence of&#xD;
      adverse events?&#xD;
&#xD;
      Background: The values for glucose, sodium, potassium and lactate in blood primes for&#xD;
      subjects weighing less than 8 kg are known to be non-physiologic. The process of priming the&#xD;
      cardiopulmonary bypass circuit is not standardized across institutions and there are several&#xD;
      methods used to correct for known prime value issues. The investigators documented the prime&#xD;
      values for 20 subjects weighing less than 8 kg and then performed pre-bypass ultrafiltration&#xD;
      (PBUF) on the prime for those same circuits to achieve more physiologic prime values. The&#xD;
      investigators were cautious not to implement too significant of a change as the investigators&#xD;
      assessed the technique and documented that plasma-free hemoglobin importantly did not rise&#xD;
      and that measured osmolality was still slightly above the normal range.&#xD;
&#xD;
      Study type: Prospective randomized controlled study.&#xD;
&#xD;
      Hypothesis: The investigators hypothesize that pre cardiopulmonary bypass ultrafiltration&#xD;
      (PBUF) can provide more physiologic prime values for glucose, sodium, potassium and lactate.&#xD;
      Plasma-free hemoglobin will not increase with the technique. Osmolality will be maintained&#xD;
      slightly above the normal range. PBUF will not negatively impact clinical outcome measures&#xD;
      and may improve them.&#xD;
&#xD;
      Specific Aim 1 To determine if use of PBUF will result in more physiologic values for&#xD;
      glucose, sodium, potassium and lactate during and immediately after cardiopulmonary bypass.&#xD;
&#xD;
      Specific Aim 2 To determine if PBUF can be achieved with no increase in plasma free&#xD;
      hemoglobin while maintaining plasma osmolality within acceptable range during and immediately&#xD;
      after cardiopulmonary bypass.&#xD;
&#xD;
      Specific Aim 3 To determine if use of PBUF will result in improved clinical outcomes after&#xD;
      surgery on cardiopulmonary bypass.&#xD;
&#xD;
      Randomization: Prior to surgery, subjects will be randomized to one of the two study groups&#xD;
      using a randomly permuted blocks design.&#xD;
&#xD;
      Statistical analysis: Analyses will be performed on an intention to treat basis. Comparisons&#xD;
      of subject characteristics and outcomes will be made using the two-sample t test or Wilcoxon&#xD;
      rank sum test for continuous variables, and Fisher's exact test for categorical variables. If&#xD;
      imbalances in patient factors exist between the two groups, linear and logistic regression&#xD;
      will be used to compare outcomes for the groups adjusting for these potential confounders.&#xD;
&#xD;
      Sample size calculation: Sample size is calculated for comparisons of subjects in the normal&#xD;
      range of values for the PBUF and standard care groups. This will be done separately for&#xD;
      glucose, sodium, potassium, and lactate; each comparison will be performed at the 0.0125&#xD;
      level of significance. If 70% of standard care subjects are in the normal range versus 90% of&#xD;
      PBUF subjects, a total of 176 subjects (88 per group) would be required to achieve 80% power.&#xD;
      With 350 eligible subjects that meet inclusion criteria based on 2017 numbers and 75% consent&#xD;
      rate the investigators will be able to enroll 260 subjects in 1 year.&#xD;
&#xD;
      Given COVID-19 restrictions, the study is on hold.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose in milligrams per deciliter (mg/dL). Normal range 61 to 199 mg/dL</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in glucose (mg/dl) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.&#xD;
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB)&#xD;
First measured levels on bypass - typically 10 minutes post initiation of bypass&#xD;
Last value on CPB&#xD;
Last value in OR&#xD;
First arrival to ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sodium in milliequivalents per liter (mEq/L). Normal range 135 to 148 mEq/L</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in sodium (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.&#xD;
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB)&#xD;
First measured levels on bypass - typically 10 minutes post initiation of bypass&#xD;
Last value on CPB&#xD;
Last value in OR&#xD;
First arrival to ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Potassium in milliequivalents per liter (mEq/L). Normal range 3.2 to 4.5 mEg/L</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in potassium (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.&#xD;
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB)&#xD;
First measured levels on bypass - typically 10 minutes post initiation of bypass&#xD;
Last value on CPB&#xD;
Last value in OR&#xD;
First arrival to ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactate in milliequivalents per liter (mEq/L). Normal range 0.5 to 2.2 mEq/L</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in lactate (mEq/L) at the following time points, and also differences in the percentage of values within the normal range for each time point, for PBUF versus standard care.&#xD;
Final prime value (in the PBUF group after completion of PBUF and prior to cardio pulmonary bypass (CPB), in the control group prior to CPB)&#xD;
First measured levels on bypass - typically 10 minutes post initiation of bypass&#xD;
Last value on CPB&#xD;
Last value in OR&#xD;
First arrival to ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osmolality in milli osmoles per kilogram (mOsm/Kg). Normal Range 276- 295 mOsm/kg</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in osmolality in mOsm/Kg in final prime, first blood draw after CPB and on arrival to cardiac intensive care unit (CICU) for PBUF versus standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma free hemoglobin in milligrams per deciliter (mg/dL). Normal &lt; 5 mg/dL.</measure>
    <time_frame>12 hours</time_frame>
    <description>Differences in plasma free hemoglobin in mg/dL in final prime, first blood draw after CPB and on arrival to cardiac intensive care unit (CICU) for PBUF versus standard care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotrope use</measure>
    <time_frame>72 hours</time_frame>
    <description>Differences in vasoactive inotrope score between the PBUF and standard care groups at the following time points:&#xD;
i. Between cessation of CPB and admission to CICU as measured by vasoactive inotrope score (VIS) ii. In CICU as measure by VIS/ 24 hours for first 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body wall edema as measured daily weights in kilograms (Kg)</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Differences in body wall edema as measure by daily weights in Kg between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body wall edema as measured daily weights in kilograms (Kg)</measure>
    <time_frame>Through study completion (until hospital discharge) , an average of 15 days.</time_frame>
    <description>Differences in body wall edema as measure by daily weights in Kg between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial ventilation duration in days and hours</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Differences in ventilation duration, Initial (days, hours) until first extubation between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintubation as a proportion subjects needing reintubation in each group Reintubation</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Difference in proportion of subjects requiring unplanned reintubation for respiratory failure between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total ventilation duration (days, hours)</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Difference in total ventilation duration (includes all periods on the ventilator including period following unplanned reintubation for respiratory failure between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Cardiac intensive care unit (CICU) length of stay (LOS) in days,</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Difference in postoperative CICU LOS in days between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hospital LOS</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Difference in postoperative hospital LOS in days between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of major adverse events (Postoperative extra corporeal membrane oxygenation (ECMO), reoperation for bleeding, reoperation for low cardiac output state, circuit clotting events) and mortality. Yes or No</measure>
    <time_frame>Through study completion (until hospital discharge), an average of 15 days.</time_frame>
    <description>Difference in proportion subjects who have a composite event between the PBUF and standard care groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PBUF used prior to Cardiopulmonary bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Use of prebypass ultrafiltration (PBUF)</intervention_name>
    <description>In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.</description>
    <arm_group_label>Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients &lt; 8 kilograms and &lt; 1 year (to ensure that all patients receive steroids&#xD;
             at initiation of CPB) undergoing an index cardiac operation for that hospitalization&#xD;
             (using a single PBUF protocol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing repeat cardiac surgery within the same admission&#xD;
&#xD;
          -  Patients undergoing transplants as their index surgery&#xD;
&#xD;
          -  Patients undergoing Ventricular assist device implantation as their index surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meena Nathan, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meena Nathan, MD, MPH</last_name>
    <phone>617-355-4308</phone>
    <phone_ext>54308</phone_ext>
    <email>meena.nathan@cardio.chboston.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Greg Matte, CCP</last_name>
    <phone>617-355-9536</phone>
    <phone_ext>59536</phone_ext>
    <email>Greg.Matte@CARDIO.CHBOSTON.ORG</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meena Nathan, MD, MPH</last_name>
      <phone>617-355-4308</phone>
      <email>meena.nathan@cardio.chboston.org</email>
    </contact>
    <contact_backup>
      <last_name>Greg Matte, CCP</last_name>
      <phone>6173557077</phone>
      <email>Greg.Matte@CARDIO.CHBOSTON.ORG</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moore GL, Peck CC, Sohmer PR, Zuck TF. Some properties of blood stored in anticoagulant CPDA-1 solution. A brief summary. Transfusion. 1981 Mar-Apr;21(2):135-7.</citation>
    <PMID>7222197</PMID>
  </reference>
  <reference>
    <citation>de Vroege R, Wildevuur WR, Muradin JA, Graves D, van Oeveren W. Washing of stored red blood cells by an autotransfusion device before transfusion. Vox Sang. 2007 Feb;92(2):130-5.</citation>
    <PMID>17298575</PMID>
  </reference>
  <reference>
    <citation>Hall TL, Barnes A, Miller JR, Bethencourt DM, Nestor L. Neonatal mortality following transfusion of red cells with high plasma potassium levels. Transfusion. 1993 Jul;33(7):606-9.</citation>
    <PMID>8333025</PMID>
  </reference>
  <reference>
    <citation>Baz EM, Kanazi GE, Mahfouz RA, Obeid MY. An unusual case of hyperkalaemia-induced cardiac arrest in a paediatric patient during transfusion of a 'fresh' 6-day-old blood unit. Transfus Med. 2002 Dec;12(6):383-6.</citation>
    <PMID>12473156</PMID>
  </reference>
  <reference>
    <citation>O'Leary MF, Szklarski P, Klein TM, Young PP. Hemolysis of red blood cells after cell washing with different automated technologies: clinical implications in a neonatal cardiac surgery population. Transfusion. 2011 May;51(5):955-60. doi: 10.1111/j.1537-2995.2010.02935.x. Epub 2010 Nov 23.</citation>
    <PMID>21091957</PMID>
  </reference>
  <reference>
    <citation>Masalunga C, Cruz M, Porter B, Roseff S, Chui B, Mainali E. Increased hemolysis from saline pre-washing RBCs or centrifugal pumps in neonatal ECMO. J Perinatol. 2007 Jun;27(6):380-4. Epub 2007 Apr 19.</citation>
    <PMID>17443201</PMID>
  </reference>
  <reference>
    <citation>Rao R, Georgieff MK. Iron in fetal and neonatal nutrition. Semin Fetal Neonatal Med. 2007 Feb;12(1):54-63. Epub 2006 Dec 6. Review.</citation>
    <PMID>17157088</PMID>
  </reference>
  <reference>
    <citation>Mumby S, Chaturvedi RR, Brierley J, Lincoln C, Petros A, Redington AN, Gutteridge JM. Iron overload in paediatrics undergoing cardiopulmonary bypass. Biochim Biophys Acta. 2000 Mar 17;1500(3):342-8.</citation>
    <PMID>10699376</PMID>
  </reference>
  <reference>
    <citation>Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic Biol Med. 2006 Nov 15;41(10):1557-65. Epub 2006 Aug 25.</citation>
    <PMID>17045924</PMID>
  </reference>
  <reference>
    <citation>Vercaemst L. Hemolysis in cardiac surgery patients undergoing cardiopulmonary bypass: a review in search of a treatment algorithm. J Extra Corpor Technol. 2008 Dec;40(4):257-67. Review.</citation>
    <PMID>19192755</PMID>
  </reference>
  <reference>
    <citation>Messent M, Sinclair DG, Quinlan GJ, Mumby SE, Gutteridge JM, Evans TW. Pulmonary vascular permeability after cardiopulmonary bypass and its relationship to oxidative stress. Crit Care Med. 1997 Mar;25(3):425-9.</citation>
    <PMID>9118657</PMID>
  </reference>
  <reference>
    <citation>Hackbarth RM, Eding D, Gianoli Smith C, Koch A, Sanfilippo DJ, Bunchman TE. Zero balance ultrafiltration (Z-BUF) in blood-primed CRRT circuits achieves electrolyte and acid-base homeostasis prior to patient connection. Pediatr Nephrol. 2005 Sep;20(9):1328-33. Epub 2005 Jun 10.</citation>
    <PMID>15947984</PMID>
  </reference>
  <reference>
    <citation>Delaney M, Axdorff-Dickey RL, Crockett GI, Falconer AL, Levario MJ, McMullan DM. Risk of extracorporeal life support circuit-related hyperkalemia is reduced by prebypass ultrafiltration. Pediatr Crit Care Med. 2013 Jul;14(6):e263-7. doi: 10.1097/PCC.0b013e31828a70c5.</citation>
    <PMID>23823207</PMID>
  </reference>
  <reference>
    <citation>Nagashima M, Imai Y, Seo K, Terada M, Aoki M, Shin√≥ka T, Koide M. Effect of hemofiltrated whole blood pump priming on hemodynamics and respiratory function after the arterial switch operation in neonates. Ann Thorac Surg. 2000 Dec;70(6):1901-6.</citation>
    <PMID>11156092</PMID>
  </reference>
  <reference>
    <citation>Grist G. Boiling the frog: the dangers of elevated sodium in blood primed pumps for infants. AmSECT Today.2012;Nov/Dec:5.</citation>
  </reference>
  <reference>
    <citation>Matte GS. Perfusion for Congenital Heart Surgery: Notes on Cardiopulmonary Bypass for a Complex Patient Population. Oxford: Wiley-Blackwell; 2015. Chapter 2, Page 27-32.</citation>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Meena Nathan</investigator_full_name>
    <investigator_title>Staff Surgeon, Department of Cardiac Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

